Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegasys plus Copegus 24 weeks versus 48 weeks in genotype 3 hepatitis C cirrhosis
2007-002743-24Phase 4Completed
- Sponsor
- Queen Mary University of London
- Start
- Mar 2008
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of interferon alfa and ribavirin in hepatitis C virus infection (2 arms), sponsored by Queen Mary University of London. Primary endpoint: Sustained virological response. Started Mar 2008; status: completed.
02
Drugs
interferon alfaribavirin
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on 2007-002743-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-002743-24.